Market Overview:
Global
Breast Cancer Market Share is projected to
grow a staggering CAGR of 9.2% during 2023 and 2032. Brest
cancer is a type of a cancer developed in breast tissue. Formation of lump in a
breast, red patches on the skin are some of the common symptoms of the breast
cancer. Obesity, lack of physical exercise, overexposure to radiation and
drinking alcohol are some of the risk factor for developing breast cancer.
According to WHO, it is the second most common type
of cancer in women. Every year 200,000 new cases are diagnosed worldwide and
this number is continuously increasing. Prevalence of breast cancer is more
common in developed countries compared to developing countries.
The
Key Competitors
Global
Breast Cancer Market Players are: Pfizer
(US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc. (UK), BioNumerik
Pharmaceuticals (US), Oncothyreon Inc. (US), Astellas (Japan), Bipar Sciences
(US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US),
AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK),
Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical
Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc.
(US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc.
(US), and Bayer AG (Germany).
Increasing number of females suffering from breast
cancer is the major factor for the growth of market. Beside this adoption of
unhealthy lifestyle, increasing female geriatric population, exposure to
harmful radiation and increasing governmental initiatives also contributed in
the growth of the market. As no absolute treatment is available there is a
scope for developing the market across the world. While on other hand high cost
of the treatment, adverse effects associated with the therapy and long approval
time for the drugs are responsible for restraining the growth of the market.
Availability of more medicines, new screening tools
gaining traction in breast cancer treatment.
The biggest change has been the approvals for treatments and available
screening tools. Over the last few years, advent breast cancer treatments have
hit the market. So the biggest thing that’s emerged in the last year that’s
really impacted the treatment is approval of medications called CDK45
Inhibitors. When used in combination with endocrine therapy for patients with
hormone-receptor positive breast cancer, the medications have shown
improvements in survival - about 10 months. In addition to promising
medications, 3-D digital tomosynthesis imaging has gained traction and became
available. Mammography allows for a more clear view of the inside of a breast. It’s
particularly useful to see through dense breast tissue. A signed bill into law
that allows commercial insurance providers to cover breast screening, including
3-D mammography.
Breast
Cancer Market – Competitive Analysis
Characterized
by the presence of several major players, having international recognition; the
global market of Breast Cancer appears to be highly fragmented and competitive.
Marketers compete based upon price and brand reinforcement. Well established
players incorporate acquisition, collaboration, partnership, expansion, and
technology launch in order to gain competitive advantage in this market and to
maintain their market position.
Breast cancer is the most commonly occurring
segment of cancer in women worldwide. The recent reports on cancer confirm the
registration of 1.7 million cases of breast cancer. Women populace in the
developed countries like U.S, U.K, and Australia are more prone to the breast
cancer than in the developing countries. Factors such as lifestyle, age,
heredity and also genetic mutations (abnormal changes) are responsible for
developing a breast cancer. The high incidence rate worldwide is becoming a
major concern and the pharmaceutical companies are increasingly investing in
research on breast cancer.
Breast
Cancer Market – Segments
The
Breast Cancer Market Outlook is segmented in
to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation
by Types: Comprises Invasive Ductal Carcinoma, Invasive Lobular Carcinoma and
other.
Segmentation
by Treatment : Comprises
Chemotherapy (Antimetabolites, Anthracyclines, Taxanes
& Alkylating Agents), Surgery & Radiation Therapy, Targeted Therapy (Tyrosine Kinase Inhibitors &Monoclonal Antibodies), Biologic
Therapy, Hormone Therapy (selective estrogen-receptor
modulators (SERMs), aromatase inhibitors) and other.
Segmentation
by End Users: Comprises Hospital Pharmacies, Private Pharmacies and others.
Segmentation
by Regions: Comprises Geographical regions - North America, Europe, APAC
and Rest of the World.
Chemotherapy accounts for the largest share of the
market; i.e. 45%.
Breast
Cancer Market – Regional Analysis
On
regional basis, global breast cancer market is dominated by America. Changing
lifestyle and increasing prevalence of breast cancer in America has driven the growth rate of breast cancer. America breast
cancer market is followed by Europe. Technological advances, increased life
expectancy and healthcare expenditure of people is responsible for the growth
of this market in America and Europe. Asia Pacific is expecting a fastest
growth for the market.
About
US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
us:
Market Research Future (part of Wantstats Research and
Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
United States of America
